<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604874</url>
  </required_header>
  <id_info>
    <org_study_id>OBOX</org_study_id>
    <nct_id>NCT03604874</nct_id>
  </id_info>
  <brief_title>High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour in Obese Women</brief_title>
  <official_title>High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour in Obese Women: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is one of the biggest public health problems of the 21st century as it increases the
      risk of many co-morbid medical conditions. Obesity in pregnancy places women at higher risk
      of obstetrical complications during pregnancy, delivery and puerperium. Obesity is a risk
      factor for cesarean delivery, failed induction of labor and labor dystocia, and prolonged
      labor curves especially among women with class III obesity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean duration from oxytocin augmentation initiation to delivery</measure>
    <time_frame>12 hours</time_frame>
    <description>the calculated time between oxytocin infusion till delivery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>DELAYED LABOUR</condition>
  <arm_group>
    <arm_group_label>low dose oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 2 mU/min, incrementally increase by 2 mU/min every 30 minutes until achievement of adequate uterine contractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 4 mU/min, incrementally increase by 4 mU/min every 30 minutes until achievement of adequate uterine contractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>high dose oxytocin</arm_group_label>
    <arm_group_label>low dose oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spontaneous onset of labor.

          -  Body mass index ≥ 30 kg/m2.

          -  Gestational age ≥ 37 weeks.

          -  Singleton pregnancy.

          -  Cephalic presentation.

          -  Reassuring fetal heart rate monitoring.

          -  Inefficient uterine contractions during active labor

          -  Women who will accept to participate in the study.

        Exclusion Criteria:

          -  Non-reassuring fetal assessment at the time of recruitment.

          -  Women received cervical ripening agents.

          -  Any patients contraindicated for vaginal delivery.

          -  Multiple gestations.

          -  Malpresentation.

          -  Previous cesarean delivery.

          -  Patients with cardiac diseases, pre-eclampsia or any other medical disorders.

          -  Fetal demise.

          -  Intrauterine growth restriction.

          -  Estimated fetal weight ≥ 5000 grams.

          -  Pre-labor rupture of membranes &gt; 24 hours.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Abbas, MD</last_name>
      <phone>00201003385183</phone>
      <email>bmr90@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

